SequelSEC

Kaya Holdings, Inc. KAYS

Pharmaceutical Preparations · CIK 0001530746 · Fiscal year ends 1231

Revenue
$26.69K
Fiscal year ended 2025-09-30
Operating income
-$1.14M
Fiscal year ended 2025-09-30
Free cash flow
Unavailable
Fiscal year ended 2025-09-30

Kaya Holdings, Inc. (KAYS) reported revenue of $26.69K and net income of -$11.74M for the fiscal year ended 2025-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Kaya Holdings, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Kaya Holdings, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Revenue$26.69K
Cost of revenue$18.97K
Gross profit$7.72K
Operating income-$1.14M
Net income-$11.74M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$377.80K
Selling & marketingUnavailable

Balance

Kaya Holdings, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Cash & equivalentsUnavailable
Total assets$199.36K
Current assets$111.69K
Total liabilities$2.92M
Current liabilities$2.53M
Total equity incl. NCI-$2.72M
Temporary (mezzanine) equityUnavailable
Inventory$348
Accounts receivable$11.74K
Goodwill$26.40K
Long-term debtUnavailable
Accounts payable$643.04K

Cash flow

Kaya Holdings, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Operating cash flow-$786.14K
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$666.61K
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$8.33K

Derived

Kaya Holdings, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Free cash flowUnavailable
Gross margin28.9%
Operating margin-4274.8%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.04x
Revenue YoY growth-58.9%
Net margin-43994.4%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KAYS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2025-11-20View SEC filing
10-Q · Filed 2025-08-27View SEC filing
10-Q · Filed 2025-05-21View SEC filing
10-K/A · Filed 2025-05-19View SEC filing
10-K · Filed 2025-04-29View SEC filing
10-Q · Filed 2024-11-22View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.